Katharine R. Clapham
( out of 88 reviews )

Katharine R. Clapham, MD

Languages spoken: English

Clinical Locations

Sugar House Health Center

Salt Lake City
801-581-2000

University of Utah Hospital

Salt Lake City
801-585-7676

  • Katharine Clapham, MD is a distinguished Assistant Professor in the Division of Cardiovascular Medicine. She has an impressive academic background, including an A.B. in Biochemical Sciences from Harvard College (2008) and an M.D. from the Health Sciences and Technology joint MIT-Harvard program at Harvard Medical School. Dr. Clapham completed her residency in Internal Medicine at Massachusetts General Hospital in Boston, MA, in 2015, and her fellowship in Cardiovascular Disease at Yale New Haven Hospital in New Haven, CT, in 2018.

    While at Yale, Dr. Clapham developed a keen interest in pulmonary vascular disease while working in a vascular biology lab. This led her to pursue further training via the Burke Advanced Fellowship in Pulmonary Heart Disease at Brigham and Women's Hospital in Boston, MA, which she successfully completed in 2022.

    Dr. Clapham's clinical and research interests are focused on pulmonary vascular disease and genetics. She is currently conducting research at the Broad Institute, exploring common and rare genetic variants that contribute to pulmonary vascular disease in the UK Biobank and Million Veteran Program.

    In addition to her impressive credentials, Dr. Clapham also serves as the Director of Pulmonary Hypertension Research and the Associate Director of the Pulmonary Hypertension and Dyspnea Program at the University of Utah. Her leadership roles in these programs further demonstrate her expertise and commitment to advancing the field of pulmonary vascular disease.

    Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Cardiovascular Disease)
    Certification Board of Nuclear Cardiology
    National Board of Echocardiography

    Patient Rating

    4.9 /5
    ( out of 88 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    October 31, 2024
    SUGAR HOUSE HEALTH CENTER

    I can't say enough good about Dr. Clapham, her expertise, patience, and professionalism.

    October 22, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr. Clapham saved my life and I'll never forget that

    October 16, 2024
    SUGAR HOUSE HEALTH CENTER

    I felt very supported and cared for by Dr. Chapman. She listened to my concerns and developed a sound treatment plan with me. So lucky to have found her and feel I am getting good care.

    October 02, 2024
    SUGAR HOUSE HEALTH CENTER

    Very thorough and helpful

    October 01, 2024
    SUGAR HOUSE HEALTH CENTER

    She takes great care in addressing every issue.

    September 16, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr. Clapham cares very much about my health issues..

    September 04, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr Clapham was very kind and personable. I felt she listened to me and took my concerns seriously. I appreciated the care I received from her.

    July 24, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr Clapham makes you feel like you are her only patient. She doesn't display she is in a hurry and is very thorough and compassionate. Her practice is undeniably patient-centered. She is very knowledgable and competent and provides excellent communication regarding the plan of care and education for self care.

    July 17, 2024
    SUGAR HOUSE HEALTH CENTER

    More testing needed - I have had testing for 1 1/2 years - needs to follow up with my doctors in Wyoming No more testing - no more visits to Utah

    See More Patient Comments

  • Katharine Clapham, MD is a distinguished Assistant Professor in the Division of Cardiovascular Medicine. She has an impressive academic background, including an A.B. in Biochemical Sciences from Harvard College (2008) and an M.D. from the Health Sciences and Technology joint MIT-Harvard program at Harvard Medical School. Dr. Clapham completed her residency in Internal Medicine at Massachusetts General Hospital in Boston, MA, in 2015, and her fellowship in Cardiovascular Disease at Yale New Haven Hospital in New Haven, CT, in 2018.

    While at Yale, Dr. Clapham developed a keen interest in pulmonary vascular disease while working in a vascular biology lab. This led her to pursue further training via the Burke Advanced Fellowship in Pulmonary Heart Disease at Brigham and Women's Hospital in Boston, MA, which she successfully completed in 2022.

    Dr. Clapham's clinical and research interests are focused on pulmonary vascular disease and genetics. She is currently conducting research at the Broad Institute, exploring common and rare genetic variants that contribute to pulmonary vascular disease in the UK Biobank and Million Veteran Program.

    In addition to her impressive credentials, Dr. Clapham also serves as the Director of Pulmonary Hypertension Research and the Associate Director of the Pulmonary Hypertension and Dyspnea Program at the University of Utah. Her leadership roles in these programs further demonstrate her expertise and commitment to advancing the field of pulmonary vascular disease.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Radiology & Imaging Sciences -Adjunct
    Academic Divisions Cardiovascular Medicine
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Cardiovascular Disease)
    Certification Board of Nuclear Cardiology
    National Board of Echocardiography

    Education history

    Fellowship Pulmonary Vascular Disease - Brigham and Women's Hospital Clinical Fellow
    Fellowship Pulmonary Hypertension - Yale University School of Medicine Postdoctoral Research Fellow
    Fellowship Cardiovascular Medicine - Yale University School of Medicine Fellow
    Residency Internal Medicine - Massachusetts General Hospital Resident
    Internship Internal Medicine - Massachusetts General Hospital Intern
    Professional Medical Medicine - Harvard Medical School M.D.
    Undergraduate Biochemical Sciences - Harvard College A.B.

    Selected Publications

    Journal Article

    1. Zon RL, Sekar A, Clapham K, Oren O, Niroula A, Bick AG, Gibson CJ, Griffin G, Uddin MM, Neuberg D, Natarajan P, Ebert BL (2024). JAK2-mutant clonal hematopoiesis is associated with venous thromboembolism. Blood, 144(20), 2149-2154. (Read full article)
    2. Ingram D, Alamri AK, Penn BA, Mayeux JD, Ma CL, Clapham KR, Abraham AE, Klanderud D, Sadeh B, Beck EM, Hatton ND, Ryan JJ (2022). Characteristics of Patients With Pulmonary Arterial Hypertension in a Pulmonary Hypertension Association-Accredited Comprehensive Care Center: A Contrast in Features When Compared With US National Registry Data. Cureus, 14(11), e31764. (Read full article)
    3. Thibord F, Klarin D, Brody JA, Chen MH, Levin MG, Chasman DI, Goode EL, Hveem K, Teder-Laving M, Martinez-Perez A, Assi D, Daian-Bacq D, Ito K, Natarajan P, Lutsey PL, Nadkarni GN, de Vries PS, Cuellar-Partida G, Wolford BN, Pattee JW, Kooperberg C, Braekkan SK, Li-Gao R, Saut N, Sept C, Germain M, Judy RL, Wiggins KL, Ko D, ODonnell CJ, Taylor KD, Giulianini F, De Andrade M, Nst TH, Boland A, Empana JP, Koyama S, Gilliland T, Do R, Huffman JE, Wang X, Zhou W, Manuel Soria J, Carlos Souto J, Pankratz N, Haessler J, Hindberg K, Rosendaal FR, Turman C, Olaso R, Kember RL, Bartz TM, Lynch JA, Heckbert SR, Armasu SM, Brumpton B, Smadja DM, Jouven X, Komuro I, Clapham KR, Loos RJF, Willer CJ, Sabater-Lleal M, Pankow JS, Reiner AP, Morelli VM, Ridker PM, Vlieg AVH, Deleuze JF, Kraft P, Rader DJ, Global Biobank Meta-Analysis Initiative Estonian Biobank Research Team 23andMe Research Team Biobank Japan CHARGE Hemostasis Working Group, Min Lee K, Psaty BM, Heidi Skogholt A, Emmerich J, Suchon P, Rich SS, Vy HMT, Tang W, Jackson RD, Hansen JB, Morange PE, Kabrhel C, Trgout DA, Damrauer SM, Johnson AD, Smith NL (2022). Cross-Ancestry Investigation of Venous Thromboembolism Genomic Predictors. Circulation, 146(16), 1225-1242. (Read full article)
    4. Lee HW, Adachi T, Pak B, Park S, Hu X, Choi W, Kowalski PS, Chang CH, Clapham KR, Lee A, Papangeli I, Kim J, Han O, Park J, Anderson DG, Simons M, Jin SW, Chun HJ (2022). BMPR1A Promotes ID2-ZEB1 Interaction to Suppress Excessive Endothelial to Mesenchymal Transition. Cardiovasc Res. (Read full article)
    5. Odanovic N, Clapham KR, Gul B, Yong CM, Meadows JL, Altin SE (2021). MENTOR study: Matching expectations and needs to optimize relationships in cardiovascular fellowship training. Am Heart J Plus, 4, 100019. (Read full article)
    6. Clapham KR, Highland KB, Rao Y, Fares WH (2020). Reduced RVSWI Is Associated With Increased Mortality in Connective Tissue Disease Associated Pulmonary Arterial Hypertension. Front Cardiovasc Med, 7, 77. (Read full article)

    Review

    1. Clapham KR, Singh I, Capuano IS, Rajagopal S, Chun HJ (2019). MEF2 and the Right Ventricle: From Development to Disease. [Review]. Front Cardiovasc Med, 6, 29. (Read full article)

    Case Report

    1. Clapham KR, Bhimani RD, Cooper JP, Stern TA (2014). Isolated shortness of breath in a woman with a history of Hodgkin lymphoma. J Intensive Care Med, 30(4), 226-8. (Read full article)

    Letter

    1. Clapham KR, Mesbah Uddin M, Honigberg MC, Gilliland T, Ruan Y, Natarajan P (2022). Venous Thromboembolism Polygenic Risk Score Associates With Pulmonary Hypertension in the UK Biobank. [Letter to the editor]. Circ Genom Precis Med, 15(6), e003797. (Read full article)
    2. Clapham KR, Rao Y, Sahay S, Sauler M, Lee PJ, Psotka MA, Fares WH, Ahmad T (2020). PECAM-1 is Associated WithOutcomes and Response to Treatment in Pulmonary Arterial Hypertension. [Letter to the editor]. Am J Cardiol, 127, 198-199. (Read full article)

  • News & Podcasts

    News